NCT03899090 is a NA clinical trial of Float pool in Generalized Anxiety Disorder, sponsored by Laureate Institute for Brain Research, Inc..

Who is sponsoring NCT03899090?

NCT03899090 is sponsored by Laureate Institute for Brain Research, Inc..

What drugs are being tested in NCT03899090?

Interventions in NCT03899090: Float pool, Float chair.

What condition does NCT03899090 study?

NCT03899090 studies Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder, Agoraphobia, Posttraumatic Stress Disorder, Major Depressive Disorder.

Is NCT03899090 still recruiting?

NCT03899090 is currently status unknown. Last updated 5 October 2023.

Last reviewed 2023-10-05 · How we verify

NCT03899090

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Floatation-REST (Reduced Environmental Stimulation Therapy) for Anxiety and Depression

Status unknown NA Last updated 5 October 2023

What this trial tests

NA trial testing Float pool in Generalized Anxiety Disorder in 75 participants. Status unknown.

Timeline

8 April 2019

Primary endpoint
30 May 2023

31 May 2024

Quick facts

Lead sponsor	Laureate Institute for Brain Research, Inc.
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	75
Start date	8 April 2019
Primary completion	30 May 2023
Estimated completion	31 May 2024
Sites	1 location across United States

Drugs / interventions tested

Float pool
Float chair

Conditions studied

Generalized Anxiety Disorder — all drugs for Generalized Anxiety Disorder →
Social Anxiety Disorder — all drugs for Social Anxiety Disorder →
Panic Disorder — all drugs for Panic Disorder →
Agoraphobia — all drugs for Agoraphobia →

Sponsor

Laureate Institute for Brain Research, Inc.

Who can join

Adults 18 to 60, any sex, with Generalized Anxiety Disorder or Social Anxiety Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This early-stage trial aims to examine the feasibility, tolerability, and safety of Floatation-REST (Reduced Environmental Stimulation Therapy) or an active comparison condition in 75 participants with clinical anxiety and depression.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

A randomized controlled safety and feasibility trial of floatation-REST in anxious and depressed individuals.
Garland MM, Wilson R, Thompson WK, Stein MB, et al · · 2024 · cited 6× · PMID 38843272 · DOI 10.1371/journal.pone.0286899
Reduced Environmental Stimulation Therapy (REST) in anxiety and depression: An experience sampling study.
Garland MM, Wilson R, Adamic E, Thompson WK, et al · · 2023 · cited 5× · PMID 38873094 · DOI 10.1016/j.xjmad.2023.100003
A randomized controlled safety and feasibility trial of floatation-REST in anxious and depressed individuals
Garland MM, Wilson R, Thompson WK, Stein MB, et al · · 2023 · DOI 10.1101/2023.05.27.23290633

Verify or expand the search:

Other recruiting trials for Generalized Anxiety Disorder

Currently open trials in the same condition.

NCT06661460 — Internet-Delivered Cognitive Behavioral Intervention for Youths With Anxiety Disorders · NA · recruiting
NCT06934525 — Implementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings · NA · recruiting
NCT07305701 — Cohort Study on Medical Students' Mental Health · recruiting
NCT07330648 — Prospective Clinical Trial of Crisugabalin Capsules in the Treatment of Generalized Anxiety Disorder · Phase 2 · recruiting
NCT07121712 — Navigated cTBS for the Treatment of Generalized Anxiety Disorder · NA · recruiting

Other Laureate Institute for Brain Research, Inc. trials

Trials by the same sponsor.

NCT06410196 — Mood and Decision-making in Methamphetamine Use Disorder · NA · recruiting
NCT06088732 — Effects of Acute Exercise and Ibuprofen on Symptoms, Immunity, and Neural Circuits in Bipolar Depression · Phase 1, PHASE2 · recruiting
NCT06219681 — Modulating Repetitive Negative Thinking Related Brain Networks in Young Adults With Depression · NA · terminated
NCT06004115 — Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression · Phase 4 · recruiting
NCT06486584 — Contingency Management for Problematic Behavior Reduction in the Community · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03899090 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Laureate Institute for Brain Research, Inc.
Last refreshed: 5 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03899090.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing